Follow us on Twitter
This page is updated frequently with new Neoplasm-related patent applications. Subscribe to the Neoplasm RSS feed to automatically get the update: related Neoplasm RSS feeds. RSS updates for this page: Neoplasm RSS
|| List of recent Neoplasm-related patents
| Methods for medical imaging|
The invention relates to methods of identifying, detecting, and locating a tissue(s), nodule(s) or mass(es) and its draining lymph nodes that is/are suspected to be abnormal, typically a neoplasm (i.e., cancer, malignancy, premalignancy) in an individual undergoing an invasive procedure (i.e., surgery or endoscopy) or a non-invasive procedure (ie. Radiology).
The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.. .
|Method for the diagnosis of myeloid neoplasias and solid tumors and diagnostic kits|
B) detecting the presence or absence of a mutation in the nucleic acid sample comprising the nf-e2 gene or a fragment thereof, characterized in that the presence of the mutation is an indication of a myeloid neoplasm or solid tumor, whereby the mutation is determined by comparing the nucleic acid sequence obtained from the sample with seq id no:1 or the complement thereof.. .
|Compounds and methods for inhibition of ap endonuclease-1/redox factor-1 (hape1) activity|
A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof.. .
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
|Gene expression signatures of neoplasm responsiveness to therapy|
Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mtori/hdaci combination therapy and/or for determining the prognosis of a neoplasm in a subject are described. Some embodiments include determining whether a neoplasm is sensitive to mtori/hdaci combination therapy by predicting whether mtori/hdaci combination therapy will successfully treat the neoplasm, for example increasing survival of the subject with the neoplasm.
|Intravascular cerebral catheter device and use|
Cerebral catheter devices and methods for use are provided. The catheter devices provided may include an anti-thrombotic agent coating on the exterior surface.
|Combination therapy using ribavirin as eif4e inhibitor|
The present invention relates to pharmaceutical compositions and combination therapies for treating patents having a neoplasm or proliferative disorder, the combination comprises an inhibitor of the eif4e gene product and a chemotherapeutic agent, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides for the use of a combination therapy for treating patients having a neoplasm, a proliferative disorder, pre-neoplasm or a precancerous lesion, comprising an inhibitor of the eif4e gene product, a chemotherapeutic agent, and a therapeutically effective amount of a hedgehog pathway inhibitor, and the method of using said combination therapy..
|Kinase inhibitors and uses thereof|
The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population..
|Neuron generation, regeneration and protection|
The invention demonstrates that, contrary to apoptotic rabies virus g proteins, certain non-apoptotic rabies virus g proteins, such as the g protein of the cvs-niv strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus g proteins, more particularly to their pdz-bs, which shows a single-point mutation compared to the one of apoptotic rabies virus g proteins.
|Bioresorbable scaffold for neurologic drug delivery|
Bioresorbable scaffolds and methods of treatment with such scaffolds for neurologic disorders including parkinson's disease, huntington's disease, alzheimer's disease, and brain neoplasms are disclosed. The bioresorbable scaffold includes a bioresorbable body and an active agent or drug associated with the body for treating or ameliorating the neurological disorder.
Differential identification of pancreatic cysts
More than 2% of adults harbor a pancreatic cyst, a subset of which progress to invasive lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of the pancreas, we determined the exomic sequences of dna from the neoplastic epithelium of eight surgically resected cysts of each of the major neoplastic cyst types: serous cystadenomas (scas), intraductal papillary mucinous neoplasms (ipmns), mucinous cystic neoplasms (mcns) and solid pseudo-papillary neoplasms (spns).
Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
The invention relates to a unique formulated pharmaceutical composition and a novel treatment method of intratumoral injection. The pharmaceutical composition of the invention is the saturated ionic solution of sodium ions and calcium ions (the “medicinal ion bomb”).
Dna methylation in colorectal and breast cancer diagnostic methods
The present invention relates generally to nucleic acid molecules in respect of which changes to dna methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to dna methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma.
9-aminomethyl substituted minocycline compounds
The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression..
Products useful for the treatment of malignant neoplasms of the human nervous system
The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human cns. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma.
Apoptosis inducing compounds
The present invention relates to compounds of formula (i), wherein r1, r2, r3, r4 and r5 are independently selected from the group comprising, inter aliae, h, optionally substituted, branched or linear c1-c12 alkyl, halogen atom and c1-c12 haloalkyl, and wherein a represents a single bond or an optionally substituted c1-c6 alkylene radical, notably useful for the treatment of human neoplasms.. .
Method of diagnosing neoplasms - ii
The present invention relates generally to nucleic acid molecules in respect of which changes to the dna or to the rna or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the dna or to the rna or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma.
Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.. .
Monitoring treatment-resistant clones in lymphoid and myeloid neoplasms by relative levels of evolved clonotypes
The invention is directed to a method of monitoring or detecting treatment-resistant clones in a patient being treated for a lymphoid or myeloid neoplasm from which patient-specific correlating clonotypes have been identified. In some embodiments, such method includes the steps of obtaining a sample from the patient comprising t-cells and/or b-cells; amplifying molecules of nucleic acid from the t-cells and/or b-cells of the sample, the molecules of nucleic acid comprising recombined dna sequences from t-cell receptor genes or immunoglobulin genes; sequencing the amplified molecules of nucleic acid to form a clonotype profile; determining from the clonotype profile a level of each correlating clonotype and clonotypes clonally evolved therefrom; and correlating a presence of a treatment-resistant clone of the neoplasm with a change in relative levels of the correlating clonotypes and clonotypes clonally evolved therefrom.
Vimentin as a biomarker for the progression of myeloproliferative neoplasms
The disclosure relates to novel compounds that are capable of modulating jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a jak2 mediated disease or disorder, and methods of use and compositions thereof.. .
Hematopoietic neoplasm chemotherapy
A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-mll based chronic myeloproliferative disorder, or non-mll based acute lymphoid leukemia is provided.. .
Methods and tools for the diagnosis and prognosis of urogenital cancers
The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly urogenital cancers. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number aberrations, at such locations correlate to specific, identifiable cancers, particularly prostate, renal, or bladder tumors.
Monitoring health and disease status using clonotype profiles
There is a need or improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Method for assessing progression of clinical state of malignant neoplasm by quantitative detection of dna in blood
The object of the invention is to provide a method for quantitatively assessing the degree of progression of a malignant neoplasm in a patient who has been medicated. Provided is a method for assessing the progression of the clinical state of a malignant neoplasm in a subject who has been administered with a medicine for treating the malignant neoplasm, the method being characterized by comprising: (1) a step of determining the ratio of dna molecules having an activation mutation that serves as an activation marker for the medicine to dna molecules having a normal marker gene in dna in the blood from the subject; (2) a step of determining the ratio of dna molecules having a resistance mutation that serves as a resistance marker for the medicine to dna molecules having a normal marker gene in the dna in the blood from the subject; and (3) a step of comparing a value obtained in the step (2) with a value obtained in the step (1) to thereby assess whether or not the malignant neoplasm in the subject has acquired resistance to the treatment with the medicine..
Method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, ef-i-delta, or m2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.. .
This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided..
Methods and compositions for single chain variable region enox2 antibodies for cancer detection and diagnosis
All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (nadh) oxidase proteins with protein disulfide-thiol interchange activity (ecto-nox proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different enox2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation.
Compositions and methods for inhibiting ccl3
The present invention relates to the discovery that ccl3, through at least one of its receptors ccr1 and ccr5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia.
Mutations in pancreatic neoplasms
To help reveal the pathogenesis of these lesions, we purified the dna from intraductal papillary mucinous neoplasm (ipmn) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of gnas.
Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy
Described are compounds capable of modulating (a) the biological activity of adp-dependent glucokinase (adpgk) and/or glycerol-3-phosphate dehydrogenase (gpd2) or (b) the expression of the gene encoding adpgk or gpd2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.. .
Cephalotaxus esters, methods of synthesis, and uses thereof
The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease.
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
A combination of a 4-anilino-3-cyanoquinoline compound (e.g. Hki-272, ski-606, ekb-569) and a capecitabine compound in the treatment of a neoplasm is provided.
Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have essential thrombocythemia (et). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having et..
Focused radiation for augmenting immune-based therapies against neoplasms
An approach combining immune-based therapies with focused radiation, including stereotactic radiation, to treat cancers is disclosed. The use of focused radiation primes the immune system in a similar manner to vaccines to augment immune-based therapies and can counteract the suppressive effects of a tumor.
Substituted tetracycline compounds
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression..
Method of diagnosing neoplasms
The present invention relates generally to a method for screening a subject for the onset, predisposition to the onset and/or progression of a colorectal neoplasm by screening for modulation in the level of expression of one or more nucleic acid markers. More particularly, the present invention provides a method for screening a subject for the onset, predisposition to the onset and/or progression of a colorectal neoplasm by screening for modulation in the level of expression of one or more gene markers in membranous microvesicles.
Enrichment of nucleic acids by complimentary capture
Assays can be used to detect mutations found in neoplasms of the pancreas, as well as for other neoplasms and other uses. Nucleic acids can be captured from body fluids such as cyst fluids.
Method for diagnosing type of pancreatic tumor
This invention is intended to provide a method capable of diagnosis of pancreatic tumor type at an early stage. More specifically, this invention relates to an examination method for determining pancreatic tumor type comprising detecting the degree of methylation in a 5′-untranslated region or a region comprising a 5′-untranslated region and a translated region of a gene encoding a mucin core protein in a pancreatic fluid sample from a subject, and identifying the pancreatic tumor as being of pancreatic tumor type selected from the group consisting of pancreatic ductal adenocarcinoma, an intraductal papillary mucinous neoplasm of the gastric type, an intraductal papillary mucinous neoplasm of the intestinal type, and an intraductal papillary mucinous neoplasm of the pancreatobiliary type using the degree of methylation as an index value..
Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
For simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating proliferative diseases, in a mammal, particularly a human, with such a combination.
Mcl-1 as a therapeutic target in scffbw7 deficient neoplasm
Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an fbw7 mutation or other fbw7 deficiency are sensitive to mcl1 inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit mcl1. Some embodiments provide methods of treating a proliferative disease based on an assessment of fbw7 expression level or mutation status.
Antineoplastic combinations containing hki-272 and vinorelbine
A combination of hki-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described..
Compositions and methods of use of phorbol esters in the treatment of neoplasms
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease.
Antibody that stops or slows tumour growth (variants)
A monoclonal antibody is described herein specifically binding to domains ii and iiic of fgfr1 or to a complex of fibroblast growth factor receptor type 1 and heparan sulphate. A method is proposed for suppressing tumour growth, based on blocking the human fibroblast growth factor/human fibroblast growth factor receptor type 1 (domains ii and iiic) pathway and involves administering the antibody.
Panel for the detection and differentiation of renal cortical neoplasms
The present invention provides a novel, highly sensitive and specific probe panel which detects the type of renal cortical neoplasm present in a biopsy sample. As such, the invention permits diagnosis of the predominant subtypes of renal cortical neoplasms without the use of invasive methods.
Predicting gastroenteropancreatic neuroendocrine neoplasms (gep-nens)
Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (gep-nen) biomarkers and agents, systems, and kits for detecting the same, and associated gep-nen diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes.. .
Cancer treatment using viruses and camptothecins
Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a sindbis virus, a picornavirus, and a myxoma virus.
Compositions and methods of aloe polysaccharides
The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis c..
Methods and materials for using the contents of phagocytes to detect neoplasms
This document provides methods and materials related to detecting premalignant or malignant neoplasms (e.g., colorectal and pancreatic cancer). For example, methods and materials for assessing the contents of phagocytes for the presence of one or more biological markers (e.g., alu repeats or methylated nucleic acid) of premalignant or malignant neoplasms are provided..
Popular terms: [SEARCH]
Neoplasm topics: Autoimmune Disease, Autoimmune, Immune Disease, Neurotoxin, Graft Versus Host Disease, Botulinum Toxin, Modulation, Human Papillomavirus, Antibodies, Ascorbic Acid, Neoplastic, Proliferative, Epithelial, Neuroblastoma, Osteosarcoma
Follow us on Twitter
This listing is a sample listing of patent applications related to Neoplasm for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Neoplasm with additional patents listed. Browse our RSS directory or Search for other possible listings.